Samumed: peers
Samumed beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Samumed: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Samumedbase 🇺🇸 US Percentile in Healthcare Percentile in USA | UnitedHealth Group Incorporated UNH · 🇺🇸 US Percentile in Healthcare Percentile in USA | Eli Lilly and Company LLY · 🇺🇸 US Percentile in Healthcare Percentile in USA | Merck & Co., Inc. MRK · 🇺🇸 US Percentile in Healthcare Percentile in USA | AbbVie Inc. ABBV · 🇺🇸 US Percentile in Healthcare Percentile in USA | Thermo Fisher Scientific Inc. TMO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Pfizer Inc. PFE · 🇺🇸 US Percentile in Healthcare Percentile in USA | Abbott Laboratories ABT · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | —— | $367.7 BOct 28, 2026 · Market data3rd of 7 | $1.20 TOct 26, 2026 · Market data1st of 7 | $359.8 BOct 19, 2026 · Market data4th of 7 | $514.0 BOct 30, 2026 · Market data2nd of 7 | $253.8 BOct 27, 2026 · Market data5th of 7 | $170.7 BOct 30, 2026 · Market data7th of 7 | $181.1 BOct 30, 2026 · Market data6th of 7 | $359.8 B7 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $447.6 BFY2025 · SEC1st of 7 | $65.2 BFY2025 · SEC2nd of 7 | $65.0 BFY2025 · SEC3rd of 7 | $61.2 BFY2025 · SEC5th of 7 | $44.6 BFY2025 · SEC6th of 7 | $62.6 BFY2025 · SEC4th of 7 | $44.3 BFY2025 · SEC7th of 7 | $62.6 B7 ranked |
| Net income (Higher is better) | —— | $12.1 BFY2025 · SEC3rd of 7 | $20.6 BFY2025 · SEC1st of 7 | $18.3 BFY2025 · SEC2nd of 7 | $4.2 BFY2025 · SEC7th of 7 | $6.7 BFY2025 · SEC5th of 7 | $7.8 BFY2025 · SEC4th of 7 | $6.5 BFY2025 · SEC6th of 7 | $7.8 B7 ranked |
| Employees (Better neither way: ranked highest first) | —— | 390,000December 31, 2025 · Profile1st of 7 | 50,000December 31, 2025 · Profile7th of 7 | 75,000December 31, 2025 · Profile4th of 7 | 57,000December 31, 2025 · Profile6th of 7 | 125,000December 31, 2025 · Profile2nd of 7 | 75,000December 31, 2025 · Profile4th of 7 | 115,000As on Dec-2022 · Profile3rd of 7 | 75,0007 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | +11.8%FY2025 · SEC2nd of 754th66th | +44.7%FY2025 · SEC1st of 782nd91st | +1.3%FY2025 · SEC6th of 729th33rd | +8.6%FY2025 · SEC3rd of 746th57th | +3.9%FY2025 · SEC5th of 734th42nd | -1.6%FY2025 · SEC7th of 722nd25th | +5.7%FY2025 · SEC4th of 739th48th | +5.7%7 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | +11.3%FY2025 · SEC2nd of 757th73rd | +31.7%FY2025 · SEC1st of 782nd92nd | +3.1%FY2025 · SEC3rd of 737th45th | +1.8%FY2025 · SEC4th of 732nd39th | -0.3%FY2025 · SEC6th of 727th32nd | -14.8%FY2025 · SEC7th of 710th6th | +0.5%FY2025 · SEC5th of 728th35th | +1.8%7 ranked |
| Earnings per share growth (Higher is better) | ———— | -14.7%FY2025 · SEC6th of 723rd25th | +96.0%FY2025 · SEC1st of 787th89th | +8.0%FY2025 · SEC2nd of 749th48th | -1.3%FY2025 · SEC4th of 735th36th | +7.3%FY2025 · SEC3rd of 748th47th | -3.5%FY2025 · SEC5th of 732nd33rd | -51.3%FY2025 · SEC7th of 710th9th | -1.3%7 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | 88.7%FY2025 · SEC1st of 691st96th | 83.0%FY2025 · SEC2nd of 684th93rd | 74.8%FY2025 · SEC3rd of 674th87th | 70.2%FY2025 · SEC5th of 669th83rd | ———— | 74.3%FY2025 · SEC4th of 673rd86th | 56.4%FY2025 · SEC6th of 647th70th | 74.6%6 ranked |
| Operating margin (Higher is better) | ———— | 4.2%FY2025 · SEC4th of 464th53rd | ———— | ———— | 24.6%FY2025 · SEC1st of 492nd90th | 17.4%FY2025 · SEC3rd of 485th82nd | ———— | 18.2%FY2025 · SEC2nd of 486th83rd | 17.8%4 ranked |
| Net margin (Higher is better) | ———— | 2.7%FY2025 · SEC7th of 765th53rd | 31.7%FY2025 · SEC1st of 795th95th | 28.1%FY2025 · SEC2nd of 793rd94th | 6.9%FY2025 · SEC6th of 773rd67th | 15.1%FY2025 · SEC3rd of 785th84th | 12.4%FY2025 · SEC5th of 782nd79th | 14.7%FY2025 · SEC4th of 785th83rd | 14.7%7 ranked |
| Free cash flow margin (Higher is better) | ———— | 3.6%FY2025 · SEC6th of 659th48th | ———— | 19.0%FY2025 · SEC2nd of 686th87th | 29.1%FY2025 · SEC1st of 696th95th | 14.1%FY2025 · SEC5th of 679th79th | 14.5%FY2025 · SEC4th of 680th80th | 16.7%FY2025 · SEC3rd of 683rd83rd | 15.6%6 ranked |
| Return on equity (Higher is better) | ———— | 12.2%FY2025 · SEC5th of 684th71st | 101.2%FY2025 · SEC1st of 699th98th | 36.9%FY2025 · SEC2nd of 696th94th | ———— | 13.0%FY2025 · SEC4th of 685th73rd | 8.9%FY2025 · SEC6th of 680th61st | 13.1%FY2025 · SEC3rd of 685th74th | 13.0%6 ranked |
| Return on invested capital (Higher is better) | ———— | 11.3%FY2025 · SEC2nd of 452nd53rd | ———— | ———— | 16.0%FY2025 · SEC1st of 466th70th | 9.0%FY2025 · SEC4th of 435th41st | ———— | 11.2%FY2025 · SEC3rd of 450th52nd | 11.2%4 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | 23.1×price Oct 28, 2026 · Market data7th of 739th60th | 43.4×price Oct 26, 2026 · Market data3rd of 767th84th | 146.7×price Oct 19, 2026 · Market data1st of 793rd97th | 49.7×price Oct 30, 2026 · Market data2nd of 771st87th | 35.9×price Oct 27, 2026 · Market data6th of 756th79th | 42.3×price Oct 30, 2026 · Market data4th of 766th83rd | 38.5×price Oct 30, 2026 · Market data5th of 759th81st | 42.3×7 ranked |
| Price to sales (Better neither way: ranked highest first) | ———— | 0.8×price Oct 28, 2026 · Market data7th of 714th25th | 13.9×price Oct 26, 2026 · Market data1st of 778th92nd | 5.3×price Oct 19, 2026 · Market data4th of 759th79th | 7.8×price Oct 30, 2026 · Market data2nd of 768th86th | 5.4×price Oct 27, 2026 · Market data3rd of 759th79th | 2.7×price Oct 30, 2026 · Market data6th of 741st56th | 3.8×price Oct 30, 2026 · Market data5th of 750th69th | 5.3×7 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | 3.7×price Oct 28, 2026 · Market data4th of 657th68th | 45.1×price Oct 26, 2026 · Market data1st of 697th98th | 6.8×price Oct 19, 2026 · Market data2nd of 676th83rd | ———— | 4.8×price Oct 27, 2026 · Market data3rd of 665th75th | 2.0×price Oct 30, 2026 · Market data6th of 637th47th | 3.5×price Oct 30, 2026 · Market data5th of 655th66th | 4.2×6 ranked |
| Free cash flow yield (Higher is better) | ———— | 4.4%price Oct 28, 2026 · Market data2nd of 684th62nd | ———— | 3.4%price Oct 19, 2026 · Market data5th of 680th56th | 3.5%price Oct 30, 2026 · Market data4th of 681st56th | 2.5%price Oct 27, 2026 · Market data6th of 677th49th | 5.3%price Oct 30, 2026 · Market data1st of 688th68th | 4.1%price Oct 30, 2026 · Market data3rd of 683rd61st | 3.8%6 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | 0.7×FY2025 · SEC3rd of 665th56th | 1.5×FY2025 · SEC6th of 686th80th | 0.9×FY2025 · SEC5th of 673rd64th | ———— | 0.7×FY2025 · SEC4th of 666th57th | 0.7×FY2025 · SEC2nd of 665th55th | 0.3×FY2025 · SEC1st of 636th27th | 0.7×6 ranked |
| Net debt to EBITDA (Lower is better) | ———— | 2.1×FY2025 · SEConly one with it53rd50th | ———— | ———— | ———— | ———— | ———— | ———— | 2.1×— |
| Interest cover (Higher is better) | ———— | 4.7×FY2025 · SEC2nd of 285th73rd | ———— | ———— | 5.2×FY2025 · SEC1st of 286th74th | ———— | ———— | ———— | 5.0×2 ranked |
| Piotroski F-score (Higher is better) | —— | 7 of 9FY2025 · SEC2nd of 6 | 7 of 9FY2025 · SEC2nd of 6 | 4 of 9FY2025 · SEC6th of 6 | 8 of 9FY2025 · SEC1st of 6 | —— | 5 of 9FY2025 · SEC5th of 6 | 6 of 9FY2025 · SEC4th of 6 | 6.5 of 96 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 19 of 30FY2025 · Scorecard3rd of 7 | 15 of 21FY2025 · Scorecard1st of 7 | 16 of 24FY2025 · Scorecard2nd of 7 | 13 of 27FY2025 · Scorecard7th of 7 | 16 of 28FY2025 · Scorecard4th of 7 | 11 of 21FY2025 · Scorecard6th of 7 | 15 of 27FY2025 · Scorecard5th of 7 | 57% passed7 ranked |
| Valuation checks (Higher is better) | —— | 2 of 6FY2025 · Scorecard2nd of 7 | 0 of 4FY2025 · Scorecard3rd of 7 | 0 of 6FY2025 · Scorecard3rd of 7 | 0 of 6FY2025 · Scorecard3rd of 7 | 0 of 6FY2025 · Scorecard3rd of 7 | 3 of 6FY2025 · Scorecard1st of 7 | 0 of 6FY2025 · Scorecard3rd of 7 | 0% passed7 ranked |
| Growth checks (Higher is better) | —— | 3 of 6FY2025 · Scorecard4th of 7 | 6 of 6FY2025 · Scorecard1st of 7 | 5 of 6FY2025 · Scorecard2nd of 7 | 2 of 6FY2025 · Scorecard6th of 7 | 4 of 6FY2025 · Scorecard3rd of 7 | 0 of 6FY2025 · Scorecard7th of 7 | 3 of 6FY2025 · Scorecard4th of 7 | 50% passed7 ranked |
| Profitability checks (Higher is better) | —— | 4 of 6FY2025 · Scorecard4th of 7 | 3 of 3FY2025 · Scorecard1st of 7 | 3 of 3FY2025 · Scorecard1st of 7 | 4 of 5FY2025 · Scorecard3rd of 7 | 3 of 6FY2025 · Scorecard7th of 7 | 2 of 3FY2025 · Scorecard4th of 7 | 4 of 6FY2025 · Scorecard4th of 7 | 67% passed7 ranked |
| Financial health checks (Higher is better) | —— | 4 of 6FY2025 · Scorecard6th of 7 | 2 of 3FY2025 · Scorecard6th of 7 | 3 of 3FY2025 · Scorecard1st of 7 | 3 of 4FY2025 · Scorecard5th of 7 | 4 of 4FY2025 · Scorecard1st of 7 | 3 of 3FY2025 · Scorecard1st of 7 | 4 of 4FY2025 · Scorecard1st of 7 | 100% passed7 ranked |
| Shareholder returns checks (Higher is better) | —— | 6 of 6FY2025 · Scorecard1st of 7 | 4 of 5FY2025 · Scorecard5th of 7 | 5 of 6FY2025 · Scorecard3rd of 7 | 4 of 6FY2025 · Scorecard7th of 7 | 5 of 6FY2025 · Scorecard3rd of 7 | 3 of 3FY2025 · Scorecard1st of 7 | 4 of 5FY2025 · Scorecard5th of 7 | 83% passed7 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 85.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 82.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 78.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 74.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 91.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 66.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 78.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | 78.5%7 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | 3,2932026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | 4,6162026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 3,9602026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 4,2722026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 2,7962026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 2,9082026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 3,0332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 3,2937 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | +5.3 pp2026-Q2 against 2026-Q1 · 13F1st of 7 | +1.3 pp2026-Q2 against 2026-Q1 · 13F6th of 7 | +2.3 pp2026-Q2 against 2026-Q1 · 13F2nd of 7 | +2.1 pp2026-Q2 against 2026-Q1 · 13F3rd of 7 | +1.6 pp2026-Q2 against 2026-Q1 · 13F4th of 7 | +1.6 pp2026-Q2 against 2026-Q1 · 13F5th of 7 | +0.9 pp2026-Q2 against 2026-Q1 · 13F7th of 7 | +1.6 pp7 ranked |
| Dividends | |||||||||
| Dividend yield (Higher is better) | ———— | 2.1%FY2025 · SEC4th of 675th51st | 0.5%FY2025 · SEC5th of 632nd13th | 2.3%FY2025 · SEC1st of 680th54th | 2.3%FY2025 · SEC1st of 680th54th | 0.3%FY2025 · SEC6th of 623rd9th | ———— | 2.3%FY2025 · SEC1st of 680th54th | 2.2%6 ranked |
| Shareholder yield (Higher is better) | ———— | 3.7%FY2025 · SEC2nd of 666th56th | 0.8%FY2025 · SEC6th of 629th19th | 3.7%FY2025 · SEC1st of 666th56th | 2.5%FY2025 · SEC4th of 653rd40th | 1.4%FY2025 · SEC5th of 639th27th | ———— | 2.8%FY2025 · SEC3rd of 658th45th | 2.6%6 ranked |
| Dividend payout (Better neither way: ranked highest first) | ———— | 65.7%FY2025 · SEC2nd of 681st73rd | 26.1%FY2025 · SEC5th of 644th32nd | 44.8%FY2025 · SEC4th of 672nd58th | 275.8%FY2025 · SEC1st of 698th97th | 9.5%FY2025 · SEC6th of 620th10th | ———— | 63.1%FY2025 · SEC3rd of 680th71st | 53.9%6 ranked |
| Dividend per share (Better neither way: ranked highest first) | —— | $8.73FY2025 · SEC1st of 7 | $6.23FY2025 · SEC3rd of 7 | $3.28FY2025 · SEC4th of 7 | $6.65FY2025 · SEC2nd of 7 | $1.72FY2025 · SEC6th of 7 | $1.72FY2025 · SEC6th of 7 | $2.40FY2025 · SEC5th of 7 | $3.287 ranked |
| Years of dividend raises (Higher is better) | —— | 15to 2025 · SEC1st of 6 | 5to 2019 · SEC5th of 6 | 15to 2025 · SEC1st of 6 | 3to 2025 · SEC6th of 6 | 8to 2025 · SEC4th of 6 | 15to 2025 · SEC1st of 6 | —— | 126 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Samumed: How market caps are worked out; UnitedHealth Group Incorporated: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Eli Lilly and Company: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Merck & Co., Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; AbbVie Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Thermo Fisher Scientific Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Pfizer Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Abbott Laboratories: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Samumed | — | — | — |
| UnitedHealth Group Incorporated | 4.2%FY2025 | 64th percentile in Healthcaremedian -7.7%, 674 companies | 53rd percentile in USAmedian 3.5%, 2,594 companies |
| Eli Lilly and Company | — | — | — |
| Merck & Co., Inc. | — | — | — |
| AbbVie Inc. | 24.6%FY2025 | 92nd percentile in Healthcaremedian -7.7%, 674 companies | 90th percentile in USAmedian 3.5%, 2,594 companies |
| Thermo Fisher Scientific Inc. | 17.4%FY2025 | 85th percentile in Healthcaremedian -7.7%, 674 companies | 82nd percentile in USAmedian 3.5%, 2,594 companies |
| Pfizer Inc. | — | — | — |
| Abbott Laboratories | 18.2%FY2025 | 86th percentile in Healthcaremedian -7.7%, 674 companies | 83rd percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Samumed | UnitedHealth Group Incorporated | Eli Lilly and Company | Merck & Co., Inc. | AbbVie Inc. | Thermo Fisher Scientific Inc. | Pfizer Inc. | Abbott Laboratories |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | $447.6 BSEC1st | $65.2 BSEC2nd | $65.0 BSEC3rd | $61.2 BSEC5th | $44.6 BSEC6th | $62.6 BSEC4th | $44.3 BSEC7th |
| 2024 | — | $400.3 BSEC1st | $45.0 BSEC5th | $64.2 BSEC2nd | $56.3 BSEC4th | $42.9 BSEC6th | $63.6 BSEC3rd | $42.0 BSEC7th |
| 2023 | — | $371.6 BSEC1st | $34.1 BSEC7th | $60.1 BSEC2nd | $54.3 BSEC4th | $42.9 BSEC5th | $59.6 BSEC3rd | $40.1 BSEC6th |
| 2022 | — | $324.2 BSEC1st | $28.5 BSEC7th | $59.3 BSEC3rd | $58.1 BSEC4th | $44.9 BSEC5th | $101.2 BSEC2nd | $43.7 BSEC6th |
| 2021 | — | $287.6 BSEC1st | $28.3 BSEC7th | $48.7 BSEC4th | $56.2 BSEC3rd | $39.2 BSEC6th | $81.3 BSEC2nd | $43.1 BSEC5th |
| 2020 | — | $257.1 BSEC1st | $24.5 BSEC7th | $41.5 BSEC4th | $45.8 BSEC2nd | $32.2 BSEC6th | $41.7 BSEC3rd | $34.6 BSEC5th |
| 2019 | — | $242.2 BSEC1st | $22.3 BSEC7th | $39.1 BSEC3rd | $33.3 BSEC4th | $25.5 BSEC6th | $40.9 BSEC2nd | $31.9 BSEC5th |
| 2018 | — | $226.2 BSEC1st | $21.5 BSEC7th | $42.3 BSEC2nd | $32.8 BSEC4th | $24.4 BSEC6th | $40.8 BSEC3rd | $30.6 BSEC5th |
| 2017 | — | $201.2 BSEC1st | $20.0 BSEC7th | $40.1 BSEC3rd | $28.2 BSEC4th | $20.9 BSEC6th | $52.5 BSEC2nd | $27.4 BSEC5th |
| 2016 | — | $184.8 BSEC1st | $21.2 BSEC5th | $39.8 BSEC3rd | $25.6 BSEC4th | $18.3 BSEC7th | $52.8 BSEC2nd | $20.9 BSEC6th |
| 2015 | — | $157.1 BSEC1st | $20.0 BSEC6th | $39.5 BSEC3rd | $22.9 BSEC4th | $17.0 BSEC7th | $48.9 BSEC2nd | $20.4 BSEC5th |
| 2014 | — | $130.5 BSEC1st | $19.6 BSEC6th | $42.2 BSEC3rd | $20.0 BSEC5th | $16.9 BSEC7th | $49.6 BSEC2nd | $20.2 BSEC4th |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Samumed#
Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- UnitedHealth Group IncorporatedUNH · 🇺🇸 USASame sector: Healthcare (Healthcare Plans) · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $367.7 B (Oct 28, 2026) · revenue $447.6 B (year to December 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Eli Lilly and CompanyLLY · 🇺🇸 USASame sector: Healthcare (Pharmaceutical) · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.20 T (Oct 26, 2026) · revenue $65.2 B (year to December 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Merck & Co., Inc.MRK · 🇺🇸 USASame sector: Healthcare (Pharmaceutical) · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $359.8 B (Oct 19, 2026) · revenue $65.0 B (year to December 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- AbbVie Inc.ABBV · 🇺🇸 USASame sector: Healthcare (Pharmaceutical) · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $514.0 B (Oct 30, 2026) · revenue $61.2 B (year to December 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Thermo Fisher Scientific Inc.TMO · 🇺🇸 USASame sector: Healthcare (Diagnostics and Research) · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $253.8 B (Oct 27, 2026) · revenue $44.6 B (year to December 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Pfizer Inc.PFE · 🇺🇸 USASame sector: Healthcare (Pharmaceutical) · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $170.7 B (Oct 30, 2026) · revenue $62.6 B (year to December 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Abbott LaboratoriesABT · 🇺🇸 USASame sector: Healthcare (Medical Devices) · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $181.1 B (Oct 30, 2026) · revenue $44.3 B (year to December 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Danaher CorporationDHR · 🇺🇸 USASame sector: Healthcare (Diagnostics and Research) · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $166.7 B (Oct 30, 2026) · revenue $24.6 B (year to December 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)+ Add
- Bristol-Myers Squibb CompanyBMY · 🇺🇸 USASame sector: Healthcare (Pharmaceutical) · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $125.5 B (Oct 30, 2026) · revenue $48.2 B (year to December 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)+ Add
- Amgen Inc.AMGN · 🇺🇸 USASame sector: Healthcare (Pharmaceutical) · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $249.2 B (Oct 30, 2026) · revenue $36.8 B (year to December 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)+ Add
- Medtronic plcMDT · 🇺🇸 USASame sector: Healthcare (Medical Devices) · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $121.2 B (Oct 29, 2026) · revenue $36.4 B (year to April 2026)45 of 100 (industry or sector 25 + country 15 + figures on file 5)+ Add
- Intuitive Surgical, Inc.ISRG · 🇺🇸 USASame sector: Healthcare (Medical Instruments) · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $155.6 B (Oct 30, 2026) · revenue $10.1 B (year to December 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.